# Clinical Characteristics and Treatment of Anosmia and Ageusia Due to SARS-CoV2 Variants

> **NCT06208540** · PHASE4 · COMPLETED · sponsor: **Sherifa Ahmed Hamed** · enrollment: 160 (actual)

## Conditions studied

- Post-covid-19 Persistent Smell and Taste Disorders

## Interventions

- **DRUG:** Cerebrolysin
- **OTHER:** olfactory and gustatory trainings

## Key facts

- **NCT ID:** NCT06208540
- **Lead sponsor:** Sherifa Ahmed Hamed
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-30
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-05-30
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2024-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06208540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06208540, "Clinical Characteristics and Treatment of Anosmia and Ageusia Due to SARS-CoV2 Variants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06208540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*